Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.

@article{Young1984PhaseIA,
  title={Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.},
  author={Charles W. Young and Violante E. Currie and Jang Hee Kim and Maureen A. O'Hehir and Fouad M. Farag and J E Kinahan},
  journal={Oncology},
  year={1984},
  volume={41 Suppl 1},
  pages={60-5}
}
Lonidamine was studied in 31 patients with different types of advanced cancer. With one exception, patients were pretreated. Lonidamine was given at 6 dosage levels from 180 to 520 mg/m2 for at least 28 days. No toxicity on hematopoietic function was observed. Side effects consisted mostly in musculoskeletal discomfort, testicular pain in males and a reversible ototoxicity. In 2 patients conjunctivitis and photophobia occurred. Plasma Lonidamine levels were measured in 14 patients. Peak… CONTINUE READING
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…